SecBot SecBot
8-K ·Filed Sep 9, 2026

TYRA

Tyra Biosciences, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed2mo ago SEC0001193125-26-385886
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Strong efficacy and safety data de-risk dabogratinib's registrational path in NMIBC and support expansion into LG UTUC and achondroplasia. Monitor upcoming data from the 70 mg cohort, FDA interactions, and initiation of the Phase 3 adjuvant study in 2027. Positive readthrough for TYRA's FGFR3 franchise value.

DirectionBullish
Confidencehigh
Horizonweeks

dabogratinib

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
Dabogratinib is in Phase 2 development across all three indications. A pivotal Phase 3 study in NMIBC is being planned following the SURF302 data, but no specific start date has been given. The earliest potential approval would likely be several years away, contingent on successful Phase 3 data and FDA review.
Next catalyst
None dated

What to watchThe next hard catalyst is the BEACH301 Phase 2 safety sentinel cohort data in pediatric achondroplasia, expected by end of Q1 2027. Positive safety and growth data could re-rate the stock after the September 2026 SURF302 selloff; negative safety signals would damage the achondroplasia thesis. Separately, watch for details on a planned pivotal Phase 3 study in NMIBC, which would be the next major binary event for the bladder cancer program.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$22.01
T+0 close · Sep 9, 2026 · via day close
Latest settled
−7.36%
T+20 · $20.39 · next T+60 in 16d
Vs SPY
−9.30%
α at T+20
Latest observation
−3.59%
T+46 · FF3 residual α
  1. T+0 · Sep 9 $22.01entry
  2. T+1 · 2mo ago +6.95%α +7.55% · $23.54
  3. T+5 · 2mo ago +10.63%α +11.73% · $24.35
  4. T+20 · 6w ago −7.36%α −9.30% · $20.39
  5. T+48 · todayOpen
  6. T+60 · in 16d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tyra Biosciences announced positive initial Phase 2 data for oral dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC, showing 79% ORR and 64% complete response rate at 60 mg QD with favorable safety (no Grade 4/5 AEs, no dose reductions). The company plans to initiate a registrational adjuvant study in 2027, targeting a >$5B market opportunity.

Key Facts

  • SURF302 Phase 2 ORR 79% (11/14) at 60 mg QD at 3-month and best overall response; CR 64% (9/14) BOR
  • No Grade 4 or 5 treatment-emergent adverse events; Grade 3 TEAEs in 14% at 60 mg; none at 60 mg were treatment-related
  • Plans to complete 60 mg enrollment, initiate 70 mg cohort, engage health authorities on Phase 3 design, and start registrational adjuvant study in 2027
  • SURF303 first LG UTUC patient achieved CR at 3 months with no TEAEs; BEACH301 cleared fifth dose level in achondroplasia cohort
  • Estimated total market opportunity for IR NMIBC >$5 billion per third-party market research

Financial Impact

Market opportunity >$5 billion for IR NMIBC; no revenue or financial data reported

market capitalizationpipeline valuation

Risk Factors

  • Initial clinical data may change as more patients are enrolled and follow-up matures
  • Regulatory path and dose selection require alignment with FDA, no guarantee of approval
  • Pre-revenue company with cash burn risk and potential future dilution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-385886
Document: 0001193125-26-385886-index-headers.html0001193125-26-385886
Document: 0001193125-26-385886-index.html0001193125-26-385886
Document: 0001193125-26-385886.txt0001193125-26-385886

Track record

13 reports on TYRA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $21.00 Now $19.74 −6.00% settles Nov 17
  2. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
  3. Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
  4. Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
  5. Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
  6. Sep 9, 20269w ago 8-K Bullish 6/10 Viewing Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
  7. Aug 4, 202614w ago 424B5 Bearish 6/10 Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
  8. Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
  9. May 13, 202626w ago 8-K Mixed 5/10 Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
  10. Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (10h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026